The acetylcholine receptor is an essential link between the brain and the muscles, so it is a sensitive location for attack. In this study, some reversible [diethylenetriaminepentaacetic acid-(amino acid) 2 ] have been docked computationally to the active site of the acetylcholine receptor. The induced fit method was employed to perform the automolecular docking for these systems. The result of docking studies generated thermodynamic properties, such as free energy of bindings (Glide score) and their weak electrostatic interactions. On the basis of these results, scintigraphic imaging studies were performed in mice. Among the radiotracers evaluated in this study, compound derived from 5-hydroxytryptophan/tryptophan exhibited remarkable localization in the brain, whereas radiotracer derived from L-histidine shows moderate accumulation in the brain. Preliminary studies with these amino acid-based ligands are encouraging to carrying out further in vivo experiments for targeted imaging.
A MINO ACIDS are necessary for the smooth functioning of cells and are crucial in all biologic processes. 1, 2 Various mechanisms have been established for the production, cell transportation, and protein incorporation of amino acids. [3] [4] [5] [6] It has been observed that most tumor cells show increased uptake of a variety of amino acids (tyrosine and methionine) compared to normal cells [7] [8] [9] and that amino acid transports are generally increased in malignant transformation. [8] [9] [10] [11] [12] [13] Other amino acids, such as histidine, tryptophan, and 5-hydroxytryptophan, contain heterocyclic moiety, that is, imidazole and indole moiety, respectively, and are the precursors of various neurotransmitters, such as histamine, serotonin, and 5-hydroxyindoleacetic acid. Clinical studies suggest significant accumulation of these amino acids in neuronal cells, whereas glutamic acid is the most abundant free amino acid in the human body and transported into tumor cells. In recent years, several natural and nonnatural amino acids have been conjugated with different chelating agents for labeling with either gamma radiation-emitting radionuclides or positronemitting radionuclides for biomedical imaging. [14] [15] [16] Diethylenetriaminepentaacetic acid (DTPA) is a wellknown chelating agent and is frequently used as a contrast agent after complexation with gadolinium. 17 It can also be easily and efficiently labeled with a radionuclide such as 99m Tc and 111 In with high radiochemical purity and stability. However, DTPA's passive and nonspecific distribution in vivo limits its utility. Various attempts have been made to decrease its side effects and to improve organ specificity by conjugation with various biovectors. 18, 19 Among them, 99m Tc-DTPA-bis (amide) derivatives have been successfully used as target-specific radiopharmaceuticals. [20] [21] [22] [23] [24] The various biologic properties of amino acids prompted us to conjugate these amino acids to a chelating agent, DTPA. The corresponding conjugates of DTPA-amino acids exhibited the properties of native amino acids and showed strong binding affinity in selective cells, specifically in the nerve region.
Nerve cells need to be able to send messages to each other quickly and clearly. One way that nerve cells communicate with their neighbors is by sending a burst of small neurotransmitter molecules. These molecules diffuse to the neighboring cell and bind to special receptor proteins in the cell surface. These receptors then open, allowing ions to flow inside. The process is fast because the small neurotransmitters, such as acetylcholine or serotonin, diffuse rapidly across the narrow synapse between the cells. The acetylcholine receptor is an essential link between the brain and the muscles, so it is a sensitive location for attack. Many organisms make poisons that block the acetylcholine receptor, causing paralysis. So we have tried to design a set of amino acid analogues [DTPA-(amino acid) 2 ] with acetylcholinesterase (AChE) interaction.
To gain insight into the molecular determinants that modulate inhibitory activity, a molecular modeling study was performed to explore the possible ligand-AChE interactions. Docking studies of DTPA-amino acid derivatives on the active site of Torpedo californica acethlcholinesterase (TcAChE) inhibited by rivastigmine (protein data bank [PDB]) identification of receptor Acetylcholinesterase [Torpedo californica]: 1GQR) revealed their mode of interaction and structural and positional requirements for potential AChE inhibition.
Preparation of Ligand
The synthetic route of ligands is shown in Figure 1 . Ligands were synthesized as follows.
Diethylenetriamine-N,N9,N99-Triacetic-N,N9-Dianhydride
Diethylenetriamine-N,N9,N99-triacetic-N,N9-dianhydride was prepared according to Zhang and colleagues. 18 The product was obtained as a white solid (93%).
DTPA-(amino acid) 2 were synthesized according to the previously reported method. 19, [24] [25] [26] The corresponding amine (2.5 mmol) was added to a solution of DTPA-bis anhydride (0.357 g, 1 mmol) in dry dimethylformamide (30 mL), and triethylamine was used to adjust the pH of the reaction mixture to around 8. The reaction mixture was stirred for an additional 48 to 72 hours at 60uC under nitrogen atmosphere. After removal of the solvent, the product was redissolved in ethanol and precipitated by the addition of diethyl ether. The precipitate was filtered off and dried in a vacuum overnight to obtain the final product in high yield ($ 80%). [DTPA-(Amino Acid) 2 ] with Acetylcholine Receptor as a Molecular Imaging Agent for SPECT Application
Radiolabeling of the Compounds with Technetium 99m
Radiolabeling of the compounds was done by following the procedure described in the literature. [25] [26] [27] [28] It was performed by taking 100 mL of 0.03 nM solution of the compounds dissolved in H 2 O and taken in a shielded vial. A further 60 mL of 1 3 10 -2 M SnCl 2 .2H 2 O (dissolved in N 2 purged 1 mL 10% acetic acid) was added followed by freshly eluted saline solution of sodium pertechnetate (NaTcO 4 ) (74 MBq, 100 mL). The pH of the reaction mixture was adjusted to 6.5 with 0.1 M NaHCO 3 solution. The vial was allowed to incubate for 20 to 30 minutes at room temperature. Labeling of the compounds, radiochemical purity, and retention factor of the 99m Tc-based complex was determined by instant thin layer chromatography-silica gel (ITLC-SG) strips using 0.9% NaCl aqueous solution (saline) as developing solvent and simultaneously in acetone and pyridine, acetic acid, and water in a 3:5:1.5 ratio. Each ITLC was cut in 0.1 cm segments, and counts of each segment were taken.
Scintigraphy in Mice
Imaging was performed in mice by administering 100 mL of the labeled conjugate (100 mg, 100 mci activity). Images were taken using a planar gamma camera equipped with a pinhole collimator and were obtained at different time intervals starting from 15 minutes to 24 hours postinjection.
Molecular Modeling Study
Molecular modeling investigations were carried out using an advanced molecular docking program, Glide, version 9.1 (Schrödinger, LLC, New York, NY). During the docking process, initially Glide performs a complete systematic search of the conformational, orientational, and positional space of the docked ligand, eliminating unwanted conformations using scoring followed by energy optimization. For our studies, the x-ray crystal structure of AChE was taken from PDB entry 1GQR, with a resolution of 2.20 Å . Solvent molecules were deleted, and the bond order for crystal ligand and protein was adjusted and minimized up to 0.30 Å root mean square deviation. Using the extra precision mode of Glide application, docking studies were performed on DTPA-amino acid derivatives. To test the capability of docking programs to deal with the diverse conformations of the same binding pocket and to predict the effects of ligand structure on docking accuracy, a diverse set of ligands was selected.
Docking Methodology
Before proceeding to the docking process, the required ligands [DTPA-(amino acids) 2 ] and target receptor (AChE) were prepared. The protein (receptor) was prepared according to the following procedure. PDB structure [1GQR (AChE)] was downloaded from a protein database (available at ,http://www.rcsb.org.) and then refined and prepared using the Schrödinger protein preparation wizard tool. All of the bound water molecules, ligands, and cofactors were removed (preprocessing) from the proteins, which were taken in fannie mae format. The tool neutralized the side chains that were not close to the binding cavity and did not participate in salt bridges. This step was then followed by restrained minimization of cocrystallized complex, which reorients side-chain hydroxyl groups and alleviates potential steric clashes. The complex obtained was minimized using an OPLS_2005 force field with a Polak-Ribière conjugate gradient algorithm. The minimization was terminated at completion of 5,000 steps or after the energy gradient converged below 0.05 kcal/mol. Van der Waals radius scaling was taken as a default absolute value less than the specified cutoff. Specific water molecules that mediate the binding between the active site amino acids and ligands were retained because these conserved water molecules play an important role as a lubricant to allow large-amplitude fluctuations of the loop structures forming the wall of the AChE active site. Hydrogen atoms were added to the receptor atoms, and input partial charges were assigned to a receptor. Finally, a receptor grid was generated for the purpose of docking.
Ligand preparation (LigPrep, Schrödinger) was used for preparing the ligands in which the correct atom and bond types were defined. Hydrogens were added, and protein charges were assigned according to the force field method. Ultimately, short energy minimization with the Glide force field was performed to release the internal strain. Finally, ligands with the ionizable group (positively charged quaternary amino group) were protonated to satisfy at the physiologic pH.
Docking experiments were carried out using an induced fit docking (IFD) program from calculations in extra precision mode. In standard virtual docking studies, ligands are docked into the binding site of a receptor, where the receptor is held rigid and the ligand is free to move. However, the assumption of a rigid receptor can provide misleading results because, in reality, many proteins undergo side-chain or backbone movements, or both, on ligand binding. These changes allow the receptor to alter its binding site so that it more closely conforms to the shape and binding mode of the ligand. This is often referred to as ''induced fit'' and is one of the main complicating factors in structure-based drug design. The docking was initiated with putting specified prepared protein and prepared ligand molecule together. IFD was run in the flexible docking mode, which automatically generates conformations for each input ligand. The combination of position and orientation of a ligand relative to the receptor, along with its conformations in flexible docking, is referred to as a ligand pose. The ligand poses that IFD generates pass through a series of hierarchial filters that evaluate the ligand's interaction with the receptor. The initial filters test the spatial fit of the ligand to the defined active site and examine the complementarities of ligand-receptor interactions using a grid-based method pattern after the empirical ChemScore function. Poses that pass their initial screens enter the final stage of the algorithm, which involves evaluation and minimization of a grid approximation to the optimized potentials for liquid simulations-(all atoms) (OPLS-AA) nonbonded ligand-receptor interaction energy. Final scoring was then carried out on the energy-minimized poses. By default, Schrödinger's proprietary Glide score multiligand scoring function was used to score the poses and analyze the results of binding affinity on the basis of the score.
Results and Discussion
This modeling study used the structure of T. californica (PDB ID: 1GQR) complexed with the AChE inhibitor rivastigmine. The enzyme monomer is an a/b serine hydrolase consisting of 532 residues. The x-ray structure of TcAChE showed that the active site of an enzyme is a deep and narrow gorge with a catalytic site composed of residues ser200, Glu327, and His440. At the entry point, a peripheral anionic site is centered by a residue, Trp279, and two aromatic residues, such as Trp84 and Phe330, represent a hydrophobic site in the enzyme. Thus, the availability of several experimentally determined threedimensional structures of AChE cocrystallized with various inhibitors provides an excellent basis for structure-based approaches to discover the new inhibitors. To understand the interaction between TcAChE and inhibitors, the enzymeligand complex was generated using the Schrödinger software (version 9.1). To compare the docking scores of ligands, we took two known inhibitors (donepezil and physostigmine) of AChE and showed their docking with the receptor as a reference interaction.
The orientation of binding inside the active site of protein may vary if the compounds have a diverse chemical space. Moreover, various conformational changes of the active site amino acids may occur during binding of compounds in the pocket. Hence, we have used induced fit (Schrödinger), a novel method for fast and accurate prediction of ligand-induced conformational changes in receptor-active sites, for studying the detailed interactions between the ligands and the active site amino acids. The induced fit protocol begins by docking the active ligand with Glide. To generate a diverse ensemble of ligand poses, the procedure uses reduced van der Waals radii and an increased Coulomb-van der Waals cutoff and can temporarily remove highly flexible side chains during the docking step. For each pose, structure prediction is then used to accommodate the ligand by reorienting nearby side chains. These residues and the ligand are then minimized. Finally, each ligand is redocked into its corresponding lowenergy protein structures and the resulting complexes are ranked according to Glide score (expanded version of the ChemScore 18 scoring function).
Docking studies with these inhibitors show that 1a to 1e are binding with a Glide score of 216.035, 213.951, 212.684, 211.275, and 210.540 (the more negative, the better the fit), respectively, and an IFD score of 21023.782, 21014.320, 21036.211, 21011.787, and 21015.255, respectively ( Table 1 ). These studies show that the 1a molecule is binding with high affinity with a total Glide energy score of 290.240, which includes the Glide evdw (hydrophobic grid potential and fraction of the total protein-ligand van der Waals energy) score 257.948, Glide ecoul (Coulomb energy) score 232.291, and extra precision H-bond score 20.523 (Glide internal energy score [einternal] 5.223, glide model energy score [emodel] 273.207, and glide ligand efficiency 20.436), as shown in Table 1 . It is evident from Figures 2 to 7 that inhibitors are stabilized by hydrogen bonding interactions (Figure 2 , Figure 3 , Figure 4 , Figure 5 , Figure 6, Figure 7 , and Figure 8 ). Table 1 shows the interaction energies score, including Glide score, evdW score, ecoul score, extra precision H-bond score, Glide energy, Glide einternal, Glide emodel, and Glide ligand efficiency for all the residues in the active site of the enzyme-inhibitor complex along with their distances and angles.
We postulated that compounds such as 1a-e may bind to TcAChE via one or more of the following: formation of a noncovalent bond between the ligand molecule and the catalytic anionic site binding unit and between the ligand molecule and the peripheral site binding unit and interactions between the ligand moiety and a hydrophobic [DTPA-(Amino Acid) 2 ] with Acetylcholine Receptor as a Molecular Imaging Agent for SPECT Application area near the surface of protein. Hydrogen bonding interactions show that the 1a molecule (DTPA-Asn) is binding with the nitrogen atom of Asn85, Gln74, Tyr121, and Ser124 and binding with the OH group of Tyr130, as shown in Table 2 . Comparison of the interaction energies of these inhibitors with other molecules shows that the 1a molecule has better binding affinity next to 1b, with a docking score or Glide score of 213.951, Glide vdW score of 259.263, Glide ecoul score of 217.908, Glide extra precision H-bond score of 20.165, and Glide energy of 277.171, as shown in Table 1 , compared to other molecules. These results show that the 1a molecule is comparatively a very good inhibitor against TcAChE. We docked all seven inhibitors, including two reference inhibitors (donepezil and physostigmine, known inhibitors of AChE), using the IFD procedure. A comparison has been done between reference inhibitor Glide scores versus other molecules, and it was found that the three compounds (1a, 1b, and 1c) had better Glide docking score and IFD scores than the reference moieties (see Table 1 ).
The top docking scores would suggest the better interaction of our compound with the target receptor AChE. Briefly, the procedure is intended to explore the flexibility of both ligand and receptor in the course of the docking process and is composed of three sequential steps: (1) initial docking of the ligand into the binding pocket of the receptor with decreased van der Waals radii of binding site amino acids; (2) optimization of the side chains of the residues in the binding pocket; and (3) final docking of the ligand at the optimized receptor. Scoring functions in the form of Glide score were evaluated for two purposes: during the docking process, they serve as fitness functions in the optimization of ligand orientation and conformation, and for comparison with other molecules, they are used as estimates of binding affinity for the completely docked molecule. Thus, the basic criteria for the quality of a scoring function are its ability to identify the currect binding mode of a ligand out of an alternative docking solution and its ability to rank related ligands with respect to their binding affinity.
The results in general also indicate all the necessary interactions between ligand and protein atoms, such as steric interactions, ligand acceptor-enzyme donor interactions, aromatic-aromatic interactions, lipophilic-lipophilic interactions, hydrogen bond interactions, hydrophobic region depiction in ligand-protein interaction, frozen rotatable bond penalty, penalty for ligand clashes with the enzyme, ligand hydrogen bond donors and acceptors, lipophilic-polar and polar-polar interaction, phenyl interaction with amides, methyl and aryl CH groups, and shape complementarity between ligand and active site of AChE an important factor for the protein interaction and protein-ligand complex interaction. Through interaction analysis, it was found that Asp72, Asn85, Tyr121, Tyr130, Trp279, Phe330, and Hie440 were important anchoring residues for the inhibitor and the main contributors to the inhibitor interaction. Apart from that, Tyr70, Gln74, Ser122, Ser124, Glu199, Asp285, Trp432, and Tyr442 residues in the receptor showed hydrogen bonding interaction with the ligands (see Table 2 ), although all the ligands showed a remarkable resemblance in the docking process as [DTPA-(Amino Acid) 2 ] with Acetylcholine Receptor as a Molecular Imaging Agent for SPECT Application they share their interaction with the common amino acid residues in the active site. The crucial ligand-receptor interaction could be defined by ligands interacting with the peripheral anionic site of the receptor through Trp279 and Phe330. The hydrophobic interaction of the ligand (1a and 1d) with the receptor was also clear as they were interacting through the aromatic ring of Phe330 in the active site. Apart from the peripheral anionic site in the enzyme AChE, their catalytic site also showed interaction with ligands through Hie440 residue, which suggests a vital ligand-receptor linkage. Although the energy contribution from the water or the extended enzyme structure was not included in interaction energy, other energy contributions reflected the satisfactory results in the form of a final docking score.
Nearly all of the DTPA-amino acid derivatives showed a very rapid clearance of radioactivity from the blood. Approximately 55 to 65% of activity was removed within 1 hour and more than 90% in 4 hours, which may be due to the hydrophilic nature of the radiotracers, which is responsible for their fast kinetics. Biodistribution of the radio complexes is an important phenomenon to study because it provides an idea about its excretory metabolic pathway and in vivo distribution of the radio complex drug.
Accumulation of a low amount of radioactivity in the stomach precludes the presence of free pertechnetate, indicative of the in vivo stability of radiotracers (Figure 9 ). The percent distribution of drug in various organs of the mice is shown as a percentage of the injected dose per organ or tissue at different time intervals. Initially, the drug was localized in the brain, heart, and liver, but with the passage of time, the activity in the kidney was amplified, whereas in the intestine, there was a negligible increase in activity. This suggests that the major route of excretion of activity is through kidneys. Also, with the passage of time, there was an increase in the accumulation of activity in the urinary bladder. Moreover, there was retention of radioactivity in the liver for a considerable period, indicating that metabolism of drugs probably takes place in the liver, but the excretion of drugs and metabolites is mainly through the kidney. Accumulation of drugs in the liver may also be because of the protein binding nature of drugs. Very high accumulation of activity was observed in the brain specifically for hydroxytryptophan amino acid/tryptophan. Negligible accumulation occurs in the lungs, spleen, and stomach.
Conclusion
The acetylcholine receptor is an essential link between the brain and the muscles and so is sensitive to attack. Many organisms make poisons that block the acetylcholine receptor, causing paralysis. We tried to design some DTPA analogues that are capable of binding more tightly at these active sites. Additional investigation to increase their specificity and to improve the pharmacokinetics performance of these new derivatives may result in potent drugs becoming available for commercial use. [DTPA-(Amino Acid) 2 ] with Acetylcholine Receptor as a Molecular Imaging Agent for SPECT Application
